Vanda Pharmaceuticals announces the publication of an article titled “Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S”
WASHINGTON, Feb. 24, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of an article entitled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S" in